System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Meta-Analysis Systematic Review Journal Article Epublish 3 citations

PubMed: 37704371 DOI: 10.1017/S095026882300153X

Immunogenicity and safety of COVID-19 vaccines among people living with HIV: A systematic review and meta-analysis.

Epidemiol Infect 151:e176

Authors: Tianyu Zhao, Zongxing Yang, Yuxia Wu, Jin Yang

Affiliations

  • Institute of Hepatology and Metabolic Diseases, Hangzhou Normal University, Hangzhou, China.
  • The Second Department of Infectious Disease, Xixi Hospital of Hangzhou, The Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
  • Institute of Hepatology and Metabolic Diseases, Hangzhou Normal University, Hangzhou, China. Department of Translational Medicine Center, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China.

Abstract

Available data suggest that the immunogenicity of COVID-19 vaccines might decrease in the immunocompromised population, but data on vaccine immunogenicity and safety among people living with HIV (PLWH) are still lacking. The purpose of this meta-analysis is to compare the immunogenicity and safety of COVID-19 vaccines in PLWH with healthy controls. We comprehensively searched the following databases: PubMed, Cochrane Library, and EMBASE. The risk ratio (RR) of seroconversion after the first and second doses of a COVID-19 vaccine was separately pooled using random-effects meta-analysis. Seroconversion rate was lower among PLWH compared with healthy individuals after the first (RR = 0.77, 95% confident interval (CI) 0.64-0.92) and second doses (RR = 0.97, 95%CI 0.95-0.99). The risk of total adverse reactions among PLWH is similar to the risk in the healthy group, after the first (RR = 0.87, 95%CI 0.70-1.10) and second (RR = 0.83, 95%CI 0.65-1.07) doses. This study demonstrates that the immunogenicity and safety of SARS-CoV-2 vaccine in fully vaccinated HIV-infected patients were generally satisfactory. A second dose was related to seroconversion enhancement. Therefore, we considered that a booster dose may provide better seroprotection for PLWH. On the basis of a conventional two-dose regimen for COVID-19 vaccines, the booster dose is very necessary.

MeSH

Seroconversion, Epidemiology, Safety, Vaccines, Covid-19 Vaccines, Hiv, Covid-19, Communicable Diseases, Infections

Cited by